// App-Quantinova.ai

e21500 : Real-world utilization and patient outcomes associated with pembrolizumab in advanced melanoma in US academic centers and affiliated satellite clinics.

Researchers

Presenter

  • Richard Wayne Joseph

Principal Investigators

  • Frank Xiaoqing Liu

  • Cynthia Macahilig

  • Scott J. Diede

  • Vaidehi Dave

  • Qing Harshaw

  • Alicia Shillington

Medical Centers

  • Mayo Clinic, Jacksonville, FL

  • Merck & Co., Inc., North Wales, PA

  • Medical Data Analytics, Parsippany, NJ

  • Merck & Co., Inc., Kenilworth, NJ

  • MDA, Parsippany, NJ

  • EPI-Q Inc., Oak Brook, IL

  • EPI-Q Inc., Oak Brook, IL

Locations

  • United States

Companies

  • Merck & Co., Inc.

  • EPI-Q, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Pembrolizumab

Outcome

  • N/A

Study Design

  • Observational

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved